





### Amended Claims

1. A prolactin lowering drug containing at least one bicyclic diterpene of the labdane or clerodane type in accordance with at least one of general formulae (I), (II), (III) or (IV):



wherein R1 = H, C<sub>1</sub> to C<sub>3</sub> alkyl or C<sub>1</sub> to C<sub>3</sub> acyl;

wherein the rings A and/or B in the case of general formulae (I) or (II) are optionally substituted in position 1, 2, 3, 6, 7, 8 or 9 with at least one OX radical, with X = H, C<sub>1</sub> to C<sub>3</sub> alkyl or C<sub>1</sub> to C<sub>3</sub> acyl;

wherein the rings A and/or B in the case of general formulae (III) or (IV) are optionally substituted in position 1, 2, 3, 4, 6, 7, or 8 with at least one OX radical, with X = H, C<sub>1</sub> to C<sub>3</sub> alkyl or C<sub>1</sub> to C<sub>3</sub> acyl;

wherein optionally at least one carbon atom in position 17, 18, 19 and 20 is substituted with an OX radical, with X = H, C<sub>1</sub> to C<sub>3</sub> alkyl or C<sub>1</sub> to C<sub>3</sub> acyl;

wherein optionally at least one CH<sub>3</sub> group in position 17, 18, 19 and 20 is replaced by one COOH group;

wherein optionally at least one of ring positions 1, 2, 3, 6, or 7 is a keto group; and


wherein optionally at least one double bond is present in ring positions 1, 2, 3, 6, 7, 8, 8(17) of formulae (I) and (III); and

wherein optionally at least one double bond is present in ring positions 1, 2, 3, 6, 7, 8, 8(17) of formula (II) and 1, 2, 3, 4(18), 6, 7, 8, 8(17) of formula (IV);


with the exception of the following compounds:

rotundifuran, sclareol, larixol acetate, 7 $\alpha$ -hydroxy-manool, (+) hardwickiic acid, crolechinic acid, hautriwaic acid, ent-15,16-epoxy-9 $\alpha$ H-labda-13(16)14-diene-3 $\beta$ ,8 $\alpha$ -diol, solidagenon and 15,16-epoxy-8(17),14,16-labdatrien-19-oic acid methyl ester.


2. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:




3. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:




4. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:




5. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:




6. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:



7. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:




8. A prolactin lowering drug according to claim 1, characterized by containing a compound having the following formula:




9. Use of a compound in accordance with any one of claims 1 to 8 for producing a prolactin lowering drug for treatment of the premenstrual syndrome, mastodynia, disorders of the menstrual cycle, in particular oligo- to amenorrhea.

10. Cleroda-Y,14-dien-13-ol, wherein Y = ring position 1, 2, 3, 4(18), 6, 7 or 8(17).



11. Use of cleroda-Y,14-dien-13-ol, wherein Y = ring position 1, 2, 3, 4(18), 6, 7 or 8(17), for producing a prolactin lowering drug or for producing a medicament for treatment of the premenstrual syndrome, mastodynia, disorders of the menstrual cycle, in particular oligo- to amenorrhea.
12. Cleroda-Y,Z,14-trien-13-ol, wherein Y or Z = ring position 1, 3, or 1, 4(18) or 1, 6 or 1, 7 or 1, 8(17) or ring position 2,4(18) or 2, 6 or 2, 7 or 2, 8(17) or ring position 4(18), 6 or 4(18), 7 or 4(18), 8(17) or ring position 6, 8(17).
13. Use of cleroda-Y,Z,14-trien-13-ol, wherein Y or Z = ring position 1, 3, or 1, 4(18) or 1, 6 or 1, 7 or 1, 8(17) or ring position 2,4(18) or 2, 6 or 2, 7 or 2, 8(17) or ring position 4(18), 6 or 4(18), 7 or 4(18), 8(17) or ring position 6, 8(17), for producing a prolactin lowering drug or for producing a medicament for treatment of the premenstrual syndrome, mastodynia, disorders of the menstrual cycle, in particular oligo- to amenorrhea.
14. Use of a compound selected from the group comprised of compounds having the following formulae:




in particular



(rotundifuran);



(sclareol); as well as



(solidagenon)

for producing a prolactin lowering drug.